Current Report Filing (8-k)
June 15 2020 - 04:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 9, 2020
Cocrystal
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38418
|
|
35-2528215
|
(State
or other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
19805
N. Creek Parkway
Bothell,
WA
|
|
98011
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (786) 459-1831
(Former
name or former address, if changed since last report.):
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
COCP
|
|
The
Nasdaq Stock Market LLC
(The Nasdaq Capital Market)
|
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
June 9, 2020, the 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) of Cocrystal Pharma, Inc. (the “Company”)
was held. At the 2020 Annual Meeting, the Company’s stockholders voted on (i) the election of five members of the Company’s
Board of Directors for a one-year term expiring at the next annual meeting of stockholders (Proposal 1), and (ii) ratification
of the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal
year ending December 31, 2020 (Proposal 2), as described in more detail in the Company’s definitive proxy statement filed
with the Securities and Exchange Commission on April 28, 2020.
Set
forth below are the voting results on each matter submitted to the stockholders at the 2020 Annual Meeting.
Proposal
1. The Company’s stockholders voted to elect the following five individuals as directors to hold office until the next
annual meeting of stockholders:
Nominee
|
|
Votes For
|
|
|
Votes Withheld
|
|
|
Broker
Non-Votes
|
|
Dr. Gary Wilcox
|
|
|
14,611,420
|
|
|
|
11,316,974
|
|
|
|
15,214,675
|
|
Dr. Phillip Frost
|
|
|
14,557,109
|
|
|
|
11,371,285
|
|
|
|
15,214,675
|
|
Mr. Roger Kornberg
|
|
|
14,571,489
|
|
|
|
11,356,905
|
|
|
|
15,214,675
|
|
Mr. Steven Rubin
|
|
|
11,456,705
|
|
|
|
14,471,689
|
|
|
|
15,214,675
|
|
Dr. Anthony Japour
|
|
|
25,812,820
|
|
|
|
115,574
|
|
|
|
15,214,675
|
|
All
five nominees were elected as directors.
Proposal
2. The Company’s stockholders voted to ratify the appointment of Weinberg & Company as the Company’s independent
registered public accounting firm for the fiscal year ending December 31, 2020.
Votes For
|
|
|
Votes Against
|
|
|
Abstentions
|
|
|
37,659,301
|
|
|
|
1,163,991
|
|
|
|
2,319,777
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Cocrystal
Pharma, Inc.
|
|
|
|
Date:
June 15, 2020
|
By:
|
/s/
James Martin
|
|
Name:
|
James
Martin
|
|
Title:
|
Chief
Financial Officer
|
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2023 to Mar 2024